In conclusion, our findings, obtained under strict quality control conditions for biological determinations and with close patient follow-up, indicate that MVD, VEGF and TS expression are not ready for ‘prime time’ and that other markers must be identified for a rational management of colon cancer patients. This evidence concerns the gene TYMS and malignant colon neoplasm.